Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

5663 - Oral cavity immune response in pancreatic ductal adenocarcinoma (PDAC)

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Juan Marquez

Citation

Annals of Oncology (2018) 29 (suppl_8): viii14-viii57. 10.1093/annonc/mdy269

Authors

J.P. Marquez, P.A. Lucero-Diaz, J.A. Matute-Briseno, M.O. Rosas-Delgado, A. CAMACHO-HERNANDEZ, Y. Cortez-Vargas, I. Nava-Sanchez, G.T. MONTANO, L.N. MONTIJO-FERNANDEZ, M.A. PEREZ-ASTORGA

Author affiliations

  • Clinical Immunooncology And Relapse Prevention Clinic, Centro de Investigacion de Cancer en Sonora-CICS, 85010 - Ciudad Obregon/MX
More

Resources

Abstract 5663

Background

We studied the humoral immune response in patients with pancreatic ductal adenocarcinoma (PDAC) using mouthwashes from the oral cavity. We found lower immune response against recall antigens, fusobacterium nucleatum and tumor associated antigens before immunotherapy treatment. We also found better prognosis when the antibodies against tested antigens got higher. Finally, we found significant differences in the humoral immune response in the oral cavity against serum.

Methods

Antigens from fusobacterium nucleatum, recall and tumor associated antigens were tested by IgG + IgM + IgA ELISA in both oral cavity and serum of PDAC patients n = 50. We provided 5 ml of saline solution to all the patients and controls to rinse the oral cavity hardly for 5 minutes and deposit the content in 15 ml tube. Sera were obtained. All was done after the approval of the local IRB committee.

Results

All the evaluated antigens were lower in the oral cavity of PDAC patients compared with controls (p = 0.001). Serum responses for all antigens were significantly different than oral cavity (p = 0.03). At the end of the immunotherapy treatment consisting in a combination of immunomodulation, multi peptide antigen specific active immunotherapy and immunogenic chemotherapy with doxorubicin and oxaliplatin the levels of antibodies were increased significantly. For example, FAP (p = 0.0001), EGFR (p = 0.005), Fascin-1 (p = 0001), VCP (P = 001). Also, the immunotherapy combination significantly increased antibody immune response against fusobaterium lysate (p = 0001).

Conclusions

PDAC is a challenge disease especially in late stages. PDAC patients had low antibody titters against several antigens in comparison with controls and before treatment the oral cavity. Serum antibodies were lower than oral cavity even after treatment. Oral cavity antibodies may be a useful early biomarker in patients in high risk of PDAC. This data also suggest that antibodies get low when the cancer or premalignant lesions of PDAC are present.

Clinical trial identification

Legal entity responsible for the study

Centro de Investigacion de Cancer en Sonora (CICS).

Funding

CICS USA.

Editorial Acknowledgement

N/A

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.